These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 27748747)

  • 21. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
    Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
    Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
    Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
    Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
    Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
    Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model.
    Rada M; Lazaris A; Kapelanski-Lamoureux A; Mayer TZ; Metrakos P
    Semin Cancer Biol; 2021 Jun; 71():52-64. PubMed ID: 32920126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.
    Sturrock M; Miller IS; Kang G; Hannis Arba'ie N; O'Farrell AC; Barat A; Marston G; Coletta PL; Byrne AT; Prehn JH
    Sci Rep; 2018 Jul; 8(1):11182. PubMed ID: 30046049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives.
    Aalders KC; Tryfonidis K; Senkus E; Cardoso F
    Cancer Treat Rev; 2017 Feb; 53():98-110. PubMed ID: 28088074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.
    Granata V; Fusco R; Catalano O; Filice S; Amato DM; Nasti G; Avallone A; Izzo F; Petrillo A
    PLoS One; 2015; 10(11):e0142876. PubMed ID: 26566221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection.
    Stremitzer S; Zhang W; Yang D; Ning Y; Sunakawa Y; Matsusaka S; Parekh A; Okazaki S; Hanna D; Astrow SH; Moran M; Hernandez J; Stephens C; Scherer SJ; Stift J; Wrba F; Gruenberger T; Lenz HJ
    Mol Cancer Ther; 2016 Nov; 15(11):2814-2821. PubMed ID: 27535973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
    [No Abstract]   [Full Text] [Related]  

  • 32. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].
    Mansueto G; Longo F
    Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711
    [No Abstract]   [Full Text] [Related]  

  • 33. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
    Qian CN; Tan MH; Yang JP; Cao Y
    Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
    Osawa G; Yoshimatsu K; Yokomizo H; Okayama S; Sagawa M; Naritaka Y
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):209-15. PubMed ID: 23670642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases.
    Rada M; Kapelanski-Lamoureux A; Petrillo S; Tabariès S; Siegel P; Reynolds AR; Lazaris A; Metrakos P
    Commun Biol; 2021 Aug; 4(1):950. PubMed ID: 34376784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance.
    Alidzanovic L; Starlinger P; Schauer D; Maier T; Feldman A; Buchberger E; Stift J; Koeck U; Pop L; Gruenberger B; Gruenberger T; Brostjan C
    Oncotarget; 2016 Aug; 7(35):57197-57212. PubMed ID: 27527865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Structural changes of tumor microenvironment in liver metastases of colorectal carcinoma].
    Giuşcă SE; Carasevici E; Eloae-Zugun F; Târcoveanu E; Căruntu ID
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):165-73. PubMed ID: 18677922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
    Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
    Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
    Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.
    Magné N; Chargari C; Levy A; Guy JB; Merrouche Y; Spano JP
    J Chemother; 2014 Aug; 26(4):253-5. PubMed ID: 24090564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.